Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.Financial_Report.xls
EX-32.1 - EXHIBIT 32.1 - Entia Biosciences, Inc.ex32_1apg.htm
EX-31.1 - EXHIBIT 31.1 - Entia Biosciences, Inc.ex31_1apg.htm
EX-32.2 - EXHIBIT 32.2 - Entia Biosciences, Inc.ex32_2apg.htm
EX-31.2 - EXHIBIT 31.2 - Entia Biosciences, Inc.ex31_2apg.htm


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

        EXCHANGE ACT OF 1934

For the Quarterly Period ended September 30, 2012


  [   ]

TRANSITION REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______ to _______.


Commission File Number:  000-52864


[ergo10q_093012apg001.jpg]


Entia Biosciences, Inc.

 (Exact name of Registrant as specified in its charter)


Nevada

26-0561199

(State or other jurisdiction

(IRS Employer

of incorporation or organization)

Identification No.)

 

13565 SW Tualatin-Sherwood Rd #800, Sherwood, OR 97140

 (Address of principal executive offices)


(503) 334-3575

 (Registrant’s telephone number)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X]   No [  ]


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive DataFile required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X]   No [  ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer [  ]

Accelerated filer [  ] 

Non-accelerated filer [  ] 

Smaller reporting company [X]


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes [  ]   No [X]


On November 14, 2012, 7,444,341 shares of the registrant's common stock, par value $0.001 per share, were outstanding.








TABLE OF CONTENTS

 

Page

Part I. Financial Information

3

 

 

Item 1.

Financial Statements

3

 

 

 

Item 2.

  Management’s Discussion And Analysis Of Financial Condition And Results Of Operations

16

 

 

 

Item 3.

Quantitative And Qualitative Disclosures About Market Risk

19

 

 

 

Item 4.

Controls And Procedures

19

 

 

Part II. Other Information

20

 

 

Item 1.

Legal Proceedings

20

 

 

 

Item 1a.

Risk Factors

20

 

 

 

Item 2.

Unregistered Sales Of Equity Securities And Use Of Proceeds

20

 

 

 

Item 3.

Defaults Upon Senior Securities

20

 

 

 

Item 4.

Mine Safety Disclosures

20

 

 

 

Item 5.

Other Information

20

 

 

 

Item 6.

Exhibits

20

 

 

 

Signatures

21




2



Part 1: FINANCIAL INFORMATION

Item 1. Financial Statements

 ENTIA BIOSCIENCES, INC.

 CONSOLIDATED BALANCE SHEETS

 

 

 

 

 

 

 

September 30, 2012

 

 

December 31, 2011

 

 

 

 

 

 

(unaudited)

 

 

 

 Assets

 

 

 

 

 

 

 

 Current Assets:

 

 

 

 

 

 

 

 Cash

 

 

$

14,698 

 

$

16,639 

 

 Accounts receivable, net

 

 

26,580 

 

 

36,273 

 

 Inventory, net

 

 

158,663 

 

 

173,578 

 

 Prepaid expenses

 

 

9,967 

 

 

31,891 

 

 

 Total Current Assets

 

 

209,908 

 

 

258,381 

 

 

 

 

 

 

 

 

 

 

 Property and Equipment, net

 

 

38,227 

 

 

31,846 

 Patents and license, net

 

 

169,604 

 

 

114,673 

 Total Assets

 

$

417,739 

 

$

404,900 

 

 

 

 

 

 

 

 

 

 

 Liabilities and Stockholders' Equity (Deficit)

 

 

 

 

 

 

 Current Liabilities:

 

 

 

 

 

 

 Accounts payable and accrued expenses

 

$

549,234 

 

$

331,839 

 

 Short-term convertible notes payable, net of discount  

 

363,277 

 

 

194,656 

 

 Capital lease payable

 

 

2,808 

 

 

 

 Notes payable

 

 

3,227 

 

 

23,157 

 

 

 Total Current Liabilities

 

 

918,546 

 

 

549,652 

 

 

 

 

 

 

 

 

 

 

 Long Term Liabilities:

 

 

 

 

 

 

 

 Capital lease payable

 

 

2,573 

 

 

 

 Convertible notes payable, net of discount-related party

 

60,470 

 

 

50,000 

 

 Convertible notes payable, net of discount

 

 

 

 

65,000 

 

 

 Total Long Term Liabilities

 

 

63,043 

 

 

115,000 

 

 

 

 

 

 

 

 

 

 

 Total Liabilities

 

 

981,589 

 

 

664,652 

 

 

 

 

 

 

 

 

 

 

 Stockholders' Equity (Deficit):

 

 

 

 

 

 

 

 Preferred stock, $0.001 par value, 5,000,000 shares authorized,

 

 

 

 

 

 

 

 Series A preferred stock, 350,000 and 350,000 shares designated,

 

 

 

 

 

 

 respectively, 88,900 and 43,500 shares issued and outstanding, 

 

 

 

 

 

 

 respectively, aggregate liquidation value of $444,500

 

 

 

 

 

 

 

 and $217,500, respectively

 

 

89 

 

 

44 

 

 Common stock, $0.001 par value, 150,000,000 shares authorized, 7,444,341

 

 

 

 

 

 

 and 7,171,175 shares issued and outstanding, respectively

7,444 

 

 

7,171 

 

 Stock subscription receivable

 

 

(59,000)

 

 

 

 Additional paid-in capital

 

 

4,903,491 

 

 

4,272,792 

 

 Deferred compensation

 

 

(377,496)

 

 

(497,383)

 

 Accumulated deficit  

 

 

(5,038,378)

 

 

(4,042,376)

 

 

 Total Stockholders' Equity (Deficit)

 

 

(563,850)

 

 

(259,752)

 

 

 

 

 

 

 

 

 

 

 Total Liabilities and Stockholders' Equity (Deficit)

$

417,739 

 

$

404,900 

 

 

 

 

 

 

 

 

 

 

 See accompanying notes to the consolidated financial statements.



3




ENTIA BIOSCIENCES, INC.

 CONSOLIDATED STATEMENTS OF OPERATIONS

 (Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months

 

Three Months

 

 

Nine Months

 

Nine Months

 

 

 

 

Ended

 

Ended

 

 

Ended

 

Ended

 

 

 

 

September 30, 2012

 

September 30, 2011

 

 

September 30, 2012

 

September 30, 2011

 

 

 

 

 

 

 

 

 

 

 

 

 REVENUES

 

$

72,604 

 

$

108,566 

 

 

$

263,255 

 

$

309,309 

 

 

 

 

 

 

 

 

 

 

 

 

 COST OF GOODS SOLD  

 

23,611 

 

15,128 

 

 

61,738 

 

100,744 

 

 

 

 

 

 

 

 

 

 

 

 

 GROSS PROFIT

 

48,993 

 

93,438 

 

 

201,517 

 

208,564 

 

 

 

 

 

 

 

 

 

 

 

 

 OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 Advertising and promotion

 

11,420 

 

11,419 

 

 

20,862 

 

82,110 

 

 Sales commissions

 

1,839 

 

 

 

5,164 

 

 

 Consulting fees - officer

 

 

30,000 

 

 

 

90,000 

 

 Professional fees

 

33,717 

 

30,986 

 

 

115,021 

 

133,460 

 

 Consulting fees  

 

38,367 

 

45,057 

 

 

192,242 

 

358,703 

 

 Impairment of intangible asset

 

 

 

 

 

106,642 

 

 General and administrative

 

193,676 

 

101,318 

 

 

667,240 

 

377,820 

 

 

 Total Operating Expenses

 

279,019 

 

218,780 

 

 

1,000,529 

 

1,148,735 

 

 

 

 

 

 

 

 

 

 

 

 

 LOSS FROM OPERATIONS

 

(230,026)

 

(125,343)

 

 

(799,012)

 

(940,171)

 

 

 

 

 

 

 

 

 

 

 

 

 OTHER INCOME (EXPENSES)

 

 

 

 

 

 

 

 

 

 

 Interest income

 

 

 

 

 

192 

 

 Interest expense

 

(50,743)

 

(75,451)

 

 

(250,905)

 

(233,766)

 

 Gain on extinguishment of debt

 

 

 

 

75,315 

 

 

 Gain on disposal of product line

 

 

 

 

 

78,842 

 

 

 Total Other Expense

 

(50,743)

 

(75,451)

 

 

(175,590)

 

(154,732)

 

 

 

 

 

 

 

 

 

 

 

 

 LOSS BEFORE TAXES  

 

(280,769)

 

(200,793)

 

 

(974,602)

 

(1,094,903)

 

 

 

 

 

 

 

 

 

 

 

 

  INCOME TAXES  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 NET LOSS

 

$

(280,769)

 

$

(200,793)

 

 

$

(974,602)

 

$

(1,094,903)

 

 

 

 

 

 

 

 

 

 

 

 

 DEEMED DIVIDEND RELATED TO BENEFICIAL

 

 

 

 

 

 

 

 

 

 

 CONVERSION FEATURE OF CONVERTIBLE

 

 

 

 

 

 

 

 

 

 

 PREFERRED STOCK

 

 

 

 

(21,400)

 

 

 

 

 

 

 

 

 

 

 

 

 

 NET LOSS PER SHARE ALLOCABLE TO COMMON

 

 

 

 

 

 

 

 

 

 STOCKHOLDERS

 

(280,769)

 

(200,793)

 

 

(996,002)

 

(1,094,903)

 

 

 

 

 

 

 

 

 

 

 

 

 NET LOSS PER COMMON SHARE

 

 

 

 

 

 

 

 

 

 

  - BASIC AND DILUTED:

 

$

(0.04)

 

$

(0.03)

 

 

$

(0.14)

 

$

(0.18)

 

 

 

 

 

 

 

 

 

 

 

 

 

 Weighted common shares outstanding

 

 

 

 

 

 

 

 

 

 

 

  - basic and diluted

 

7,209,206 

 

6,197,676 

 

 

7,190,229 

 

6,149,050 

 

 

 

 

 

 

 

 

 

 

 

 

 See accompanying notes to the consolidated financial statements.



4






ENTIA BIOSCIENCES, INC.

 CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)

 FOR THE PERIOD ENDED DECEMBER 31, 2011 AND  

 

 FOR THE INTERIM PERIOD ENDED SEPTEMBER 30, 2012

 (Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

 

Total

 

 

 

 

 

Preferred Stock

 

Common Stock

 

Paid

 

Deferred

 

Stock

 

Accumulated

 

Stockholders'

 

 

 

 

 

Shares

 

Amount

 

Shares

 

 

Amount

 

In Capital

 

Compensation

 

Subscriptions

 

Deficit

 

Equity (Deficit)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Balance - December 31, 2010

 

 

-

 

$

-

 

5,836,247

 

 

$

5,836

 

$

2,011,989

 

$

(9,704)

 

$

 

$

(2,313,274)

 

$

(305,153)

 Conversion of note payable into preferred stock

 

21,500

 

22

 

-

 

 

-

 

107,478

 

 

 

 

 

107,500 

 Issuance of preferred stock for cash

 

22,000

 

22

 

-

 

 

-

 

109,978

 

 

 

 

 

110,000 

 Issuance of warrants in connection with

 

 

 

 

 

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 convertible notes payable

 

 

-

 

-

 

-

 

 

-

 

45,937

 

 

 

 

 

45,937 

 Beneficial conversion feature in connection with

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 convertible note payable

 

 

-

 

-

 

-

 

 

-

 

173,030

 

 

 

 

 

173,030 

 Issuance of common stock for license agreement

 

-

 

-

 

100,000

 

 

100

 

99,900

 

 

 

 

 

100,000 

 Issuance of common stock for conversion of accounts

-

 

-

 

-

 

 

-

 

-

 

 

 

 

 

 

 payable/accrued comp

 

 

 

 

 

 

897,104

 

 

935

 

368,875

 

 

 

 

 

369,810 

 Issuance of common stock for services

 

-

 

-

 

276,395

 

 

238

 

243,758

 

 

 

 

 

243,996 

 Issuance of common stock and warrants for cash

 

-

 

-

 

61,429

 

 

62

 

42,938

 

 

 

 

 

43,000 

 Stock compensation

 

 

-

 

-

 

-

 

 

-

 

347,696

 

 

 

 

 

347,696 

 Issuance of warrants for services

 

 

-

 

-

 

-

 

 

-

 

721,213

 

(712,758)

 

 

 

 

8,455 

 Amortization of deferred compensation

 

-

 

-

 

-

 

 

-

 

-

 

225,079 

 

 

 

 

225,079 

 Net loss

 

 

-

 

-

 

-

 

 

-

 

-

 

 

 

 

(1,729,103)

 

(1,729,103)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Balance -December 31, 2011

 

 

43,500

 

44

 

7,171,175

 

 

7,171

 

4,272,792

 

(497,383)

 

 

(4,042,376)

 

(259,752)

 Issuance of preferred stock for cash

 

36,400

 

36

 

-

 

 

-

 

181,963

 

 

 

 

181,999 

 Issuance of preferred stock for  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 cancellation of debt

 

 

2,000

 

2

 

-

 

 

-

 

9,998

 

 

 

 

10,000 

 Issuance of preferred stock for services

 

7,000

 

7

 

-

 

 

-

 

34,993

 

 

 

 

35,000 

 Deemed dividend related to beneficial conversion

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 feature of convertible preferred stock

 

-

 

-

 

-

 

 

-

 

21,400

 

 

 

(21,400)

 

 Issuance of warrants in connection with

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 convertible notes payable

 

 

-

 

-

 

-

 

 

-

 

27,704

 

 

 

 

27,704 

 Issuance of common stock for license agreement

 

-

 

-

 

50,000

 

 

50

 

25,451

 

 

 

 

25,501 

 Issuance of common stock and warrants for cash

 

-

 

-

 

75,000

 

 

75

 

29,925

 

 

 

 

30,000 

 Issuance of common stock for note receivable

 

-

 

-

 

147,500

 

 

147

 

58,853

 

 

(59,000)

 

 

 Stock compensation

 

 

-

 

-

 

666

 

 

1

 

170,740

 

 

 

 

170,741 

 Issuance of warrants for services

 

 

-

 

-

 

-

 

 

-

 

21,139

 

(21,139)

 

 

 

 Issuance of warrants for extension on debt

 

-

 

-

 

-

 

 

-

 

48,533

 

 

 

 

48,533 

 Amortization of deferred compensation

 

-

 

-

 

-

 

 

-

 

-

 

141,026 

 

 

 

141,026 

 Net loss

 

 

-

 

-

 

-

 

 

-

 

-

 

 

 

(974,602)

 

(974,602)

 Balance - September 30, 2012

 

 

88,900

 

$

89

 

7,444,341

 

 

$

7,444

 

$

4,903,491

 

$

(377,496)

 

$

(59,000)

 

$

(5,038,378)

 

$

(563,850)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 See accompanying notes to the consolidated financial statements.



5






ENTIA BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 (Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months

 

 

Nine Months

 

 

 

 

 

 

 

 

 

 

 

 

 

Ended

 

 

Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30, 2012

 

 

September 30, 2011

 

 CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Net loss

 

 

 

 

 

 

 

 

$

(974,602)

 

$

(1,094,903)

 

 Adjustments to reconcile net loss to net cash

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 used in operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Gain on disposal of product line

 

 

 

 

 

 

 

 

 

 

 

(78,842)

 

 

 Bad debt expense

 

 

 

 

 

 

 

 

 

 

 

2,059 

 

 

 Depreciation/amortization

 

 

 

 

 

 

 

 

 

16,290 

 

 

11,009 

 

 

 Gain on extinguishment of debt

 

 

 

 

 

 

 

 

 

(75,315)

 

 

 

 

 Impairment of intangible asset

 

 

 

 

 

 

 

 

 

 

 

106,642 

 

 

 Amortization of discount on convertible notes

 

 

 

 

 

 

 

 

 

179,110 

 

 

222,933 

 

 

 Stock-based compensation

 

 

 

 

 

 

 

 

 

420,801 

 

 

467,131 

 

 

 Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Accounts receivable

 

 

 

 

 

 

 

 

 

9,693 

 

 

(11,433)

 

 

 

 Inventory

 

 

 

 

 

 

 

 

 

14,915 

 

 

(23,501)

 

 

 

 Prepaid expenses

 

 

 

 

 

 

 

 

 

21,924 

 

 

24,930 

 

 

 

 Other current assets

 

 

 

 

 

 

 

 

 

 

 

3,792 

 

 

 

 Accounts payable and accrued expenses

 

 

 

 

 

 

 

 

 

217,395 

 

 

95,045 

 

 

 

 Accrued compensation - officer

 

 

 

 

 

 

 

 

 

 

 

89,398 

 

 NET CASH USED IN OPERATING ACTIVITIES

 

 

 

 

 

 

 

 

 

(169,789)

 

 

(185,740)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Purchase of property and equipment

 

 

 

 

 

 

 

 

 

(14,906)

 

 

(3,708)

 

 

 Acquisition of patents and patents pending  (net)

 

 

 

 

 

 

 

 

 

(57,315)

 

 

(34,789)

 

 

 Collections on lease receivable

 

 

 

 

 

 

 

 

 

 

 

8,304 

 

 NET CASH USED IN INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

 

(72,221)

 

 

(30,193)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Proceeds from issuance of common stock, preferred stock and warrants

211,999 

 

 

143,200 

 

 

 Proceeds from convertible notes payable

 

 

 

 

 

 

 

 

 

13,000 

 

 

 

 

 Proceeds from notes payable

 

 

 

 

 

 

 

 

 

 

 

26,438 

 

 

 Proceeds from convertible note payable-related party

 

 

 

 

 

 

 

 

25,000 

 

 

 

 

 Repayment of note payable

 

 

 

 

 

 

 

 

 

(9,930)

 

 

(10,795)

 

 NET CASH PROVIDED BY FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

 

240,069 

 

 

158,843 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 NET CHANGE IN CASH

 

 

 

 

 

 

 

 

 

(1,941)

 

 

(57,090)

 

 Cash at beginning of period

 

 

 

 

 

 

 

 

 

16,639 

 

 

65,061 

 

 Cash at end of period

 

 

 

 

 

 

 

 

$

14,698 

 

$

7,971 

 

 SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:

 

 

 

 

 

 

 

 

 Interest paid

 

 

 

 

 

 

 

 

$

893 

 

$

1,674 

 

 

 Taxes paid

 

 

 

 

 

 

 

 

$

 

$

 

 SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING

 

 

 

 

 

 

 

 AND INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Deemed distribution

 

 

 

 

 

 

 

 

$

21,400 

 

$

 

 

 Conversion of notes payable to preferred stock

 

 

 

 

 

 

 

 

$

10,000 

 

$

107,500 

 

 

 Warrants issued for extinguishment of debt

 

 

 

 

 

 

 

 

$

48,533 

 

$

 

 

 Stock issued for license

 

 

 

 

 

 

 

 

$

25,501 

 

$

100,000 

 

 

 Stock issued for note receivable

 

 

 

 

 

 

 

 

$

59,000 

 

 

 

 

 Warrants issued in connection with notes payable

 

 

 

 

 

 

 

 

$

27,704 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 See accompanying notes to the consolidated financial statements.



6




NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND OPERATIONS

Generic Marketing Services, Inc. was incorporated on July 19, 2007 under the laws of the State of Nevada as a subsidiary of Basic Services, Inc., also a Nevada corporation.  On December 31, 2007, Basic Services, Inc. spun off Generic Marketing Services and on October 8, 2008, Generic Marketing Services changed its name to Total Nutraceutical Solutions, Inc.  On January 9, 2012, the Nevada Secretary of State accepted an amendment to our Articles of Incorporation to change the name again to Entia Biosciences, Inc. (Entia, the Company, us, we or our) and to form a wholly owned subsidiary named Total Nutraceutical Solutions, Inc. (TNS)  Entia is an emerging biotechnology company engaged in the discovery, formulation and marketing of natural compounds and whole foods that can be used in branded medical foods, nutraceuticals, cosmetics and other products sold by us, our TNS subsidiary and by third parties.


On February 15, 2012 a 10:1 reverse stock split became effective after we received authorization from Financial Industry Regulatory Authority (FINRA) for the corporate action that was approved by the shareholders on December 19, 2011.


On May 15, 2012, Entia moved from its current location to a larger building in order to increase its in-house research and manufacturing capability, increase its warehouse storage capacity, and accommodate anticipated increases in order fulfillment and staffing.  By moving to the larger facility, Entia was able to vertically integrate its Vitamin D enhancement technology and the milling, blending, encapsulating, bottling, labeling, packaging and fulfillment of its products. This move resulted in a significant improvement in production efficiencies and the cost of its final products.  Production of cosmetic products and certain nutraceuticals are still being outsourced.


We have a history of incurring net losses and net operating cash flow deficits.  We are continually researching and developing new technologies related to our organic nutraceutical products, including the production of medical foods for clinical studies in diabetes, anemia and Parkinson’s disease.  At September 30, 2012, we had cash and cash equivalents of $14,698.  These conditions raise substantial doubt about our ability to continue as a going concern.  As a result, we anticipate that our cash and cash equivalent balances, anticipated cash flows from operations and anticipated operating cash flows will be sufficient to meet our cash requirements through December 2012.  


In order for us to continue as a going concern beyond this point and ultimately to achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs.  The issuance of equity securities will also cause dilution to our shareholders.  If external financing sources of financing are not available or are inadequate to fund our operations, we will be required to reduce operating costs including personnel costs, which could jeopardize our future strategic initiatives and business plans.  The accompanying consolidated financial statements have been prepared assuming that the company continues as a going concern.


The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES


Basis of presentation and principles of consolidation


The accompanying consolidated unaudited interim financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP) for interim financial information, and with the rules and regulations of the United states Securities and Exchange Commission (“SEC”) to Form 10-Q and Article 8 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented.  Unaudited interim results are not necessarily indicative of the results for the full year.  These unaudited interim financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2011 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC.  


Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. The consolidated financial statements include the accounts of Entia and TNS.  All intercompany accounts have been eliminated for the purpose of the consolidated financial statement presentation.



7




Use of estimates


The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.


Cash


We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.


Accounts receivable


Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts.  The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable.  Outstanding account balances are reviewed individually for collectibility.  We determine the allowance based on historical write-off experience, customer specific facts and economic conditions.  Bad debt expense is included in general and administrative expenses, if any.  We consider all accounts greater than 30 days old to be past due.  Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote.  The allowance for doubtful accounts was $2,526 and $2,526 at September 30, 2012 and December 31, 2011, respectively.


Inventory


Inventory, which consists primarily of raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the first-in, first-out method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory.   


Property and equipment


Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred.  Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations.  Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets:


Office equipment

 

3 years

Production equipment

 

5 to 7 years

Equipment under capital lease

 

5 to 7 years

Leasehold improvements

 

Lesser of lease term or useful life of improvement


Patents


Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs.  Patent application costs, generally legal costs, are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected.  The costs of defending and maintaining patents are expensed as incurred.  Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.


Impairment of long-lived assets


Our long-lived assets, which include property and equipment, patents and licenses of patents, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.


We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets.  Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.  If long-lived assets are



8



determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.  

 

Discount on convertible notes payable


We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument.  The amortization is recorded as interest expense on the consolidated statement of operations.


Fair value of financial instruments


The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments.  Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes.


Fair value measurements


We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:


Level 1

 

Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.

 

 

 

Level 2

 

Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.

 

 

 

Level 3

 

Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.


We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at September 30, 2012 or December 31, 2011, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the periods ended September 30, 2012 and December 31, 2011.


Revenue recognition


We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured.


Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive.


Shipping and handling costs


Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred.  


Advertising and promotion costs


Costs associated with the advertising and promotion of our products are expensed as incurred.


Equity instruments issued to parties other than employees for acquiring goods or services



9



We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur.  Currently such transactions are primarily awards of warrants to purchase common stock.


The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model.  


The assumptions used to determine the fair value of our warrants are as follows:


The expected life of warrants issued represents the period of time the warrants are expected to be outstanding.

 

The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant.

 

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant.

 

The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant.


Income taxes


We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date.


We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.  Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense.


Net loss per common share


Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for three months ending September 30, 2012 and 2011 and the nine months ending September 30, 2012 and 2011.   The following table presents a reconciliation of basic loss per share and excluded dilutive securities:


 

 

 

For the Three Months Ended September 30,

 

For the Nine Months Ended September 30,

 

 

 

2012

 

2011

 

2012

 

2011

 Numerator:

 

 

 

 

 

 

 

 

 Net loss applicable to common shareholders

$

(280,769)

 

$

(200,793)

 

$

(996,002)

 

$

(1,094,903)

 Denominator:

 

 

 

 

 

 

 

 

 Weighted-average common shares outstanding

7,209,206 

 

6,197,676 

 

7,190,229 

 

6,149,050 

 Basic and diluted net loss per share

$

(0.04)

 

$

(0.03)

 

$

(0.14)

 

$

(0.18)

 Common stock warrants

2,758,266 

 

1,689,747 

 

2,464,471 

 

1,689,747 

 Series A convertible preferred stock

889,000 

 

415,000 

 

843,000 

 

415,000 

 Stock options

 

658,240 

 

 

591,179 

 

 Convertible debt including interest

400,025 

 

537,865 

 

395,624 

 

537,865 

 Excluded dilutive securities

4,705,531 

 

2,642,612 

 

4,294,274 

 

2,642,612 




10




Reclassifications 


Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation.


Segments


We have determined that we operate in one segment for financial reporting purposes.


Recently issued accounting pronouncements


Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.


NOTE 3 – INVENTORY


Inventory consists of the following:


 

 

 

September 30,

2012

 

December 31,

2011

 Raw materials

 

$

278,797 

 

$

294,036 

 Finished goods

 

7,439 

 

7,115 

 

 

 

286,236 

 

301,151 

 Less:  reserve for excess and obsolete inventory

(127,573)

 

(127,573)

 

 

 

$

158,663 

 

$

173,578 



NOTE 4 – PROPERTY AND EQUIPMENT


Property and equipment, stated at cost, consists of the following:


 

 

 

September 30,

2012

 

December 31,

2011

 Office equipment

 

$

24,584 

 

$

23,072 

 Production equipment

37,984 

 

30,964 

 Leasehold improvements

13,946 

 

2,192 

 

 

 

76,514 

 

56,228 

 Less:  accumulated depreciation

(38,287)

 

(24,382)

 

 

 

$

38,227 

 

$

31,846 



NOTE 5 - PATENTS AND LICENSES, NET


Our identifiable long-lived intangible assets are patents and prepaid licenses.  Patent and license amortization is $803 and $178 for the three months ended September 30, 2012 and 2011, respectively and $2,383 and $251 for the nine months ended September 30, 2012 and 2011, respectively.  


The licenses are being amortized over an economic useful life of 17 years. The gross carrying amounts and accumulated amortization related to these intangible assets consist of the following at:


 

 

 

September 30,

2012

 

December 31,

2011

 Gross carrying amounts-patents and licenses

$

174,238 

 

$

116,924 

 Accumulated amortization

(4,634)

 

(2,251)

 Patents and Licenses, net

$

169,604 

 

$

114,673 




11



NOTE 6 – CAPITAL LEASE


In April 2012, we entered into a capital lease agreement totaling $7,021 for the lease of an encapsulating machine used to encapsulate our powdered product.  The lease is payable over 30 months interest free.


The following is a schedule by years of future minimum lease payments under capital leases.  


Years ending December 31:

 

2012

$

702

2013

$

2,808

2014

$

1,871

Total minimum lease payments

$

5,381



NOTE 7 – NOTES PAYABLE


Notes payable consists of the following:


 

 

 

September 30, 2012

 

December 31, 2011

Notes payable - current

 

 

 

4.85%, unsecured, due monthly

415 

 

20,664 

7.85% unsecured, due monthly

2,812 

 

2,493 

 

 

 

$

3,227 

 

$

23,157 

Convertible notes payable, net

 

 

 

5% unsecured due June 2013 (net of discount related to beneficial conversion feature of $0 in 2012 and $5,143 in 2011), convertible into preferred stock at $5.00 per share

$

15,000 

 

$

9,857 

5%, unsecured due June 2013  (net of discount related to beneficial conversion feature of $35,807 in 2012 and $127,701 in 2011), convertible into common stock at $0.45 per share

276,693 

 

184,799 

6% unsecured due June 2013 (net of discount related to beneficial conversion feature of $6,416 in 2012 and $0 in 2011), convertible into preferred stock at $5.00 per share

6,584 

 

 

5% unsecured due June 2013, convertible into preferred stock at $5.00  per share

15,000 

 

15,000 

6% unsecured, convertible into common stock at $2.00 per share, due on demand

50,000 

 

50,000 

Less:  Current Portion

(363,277)

 

(194,656)

 

 

 

$

 

$

65,000 

 

 

 

 

 

 

Convertible notes payable related party, net

 

 

 

6% unsecured due December 2013 (net of discount related to beneficial conversion feature of $14,530 in 2012 and $0 in 2011), convertible into common stock at $2.00 per share

$

60,470 

 

$

50,000 



Entia had debt in the principal amount of $392,500 in the form of convertible notes payable of which $377,500 was to mature on June 30, 2012.  Entia was successful in renegotiating all but one of these notes to extend their maturity dates to June 30, 2013.  $50,000 of the debt was extended month-to-month, and as such, all is classified as short-term on the balance sheet.  In consideration for extending the maturity date, Entia issued 50,000 warrants valued at $48,533 and modified an existing conversion feature for one of the notes.



12




For one of the convertible notes payable modified in the second quarter, we deemed the terms of the note modification to be substantially different due to the change in the conversion rate and treated the convertible note payable as extinguished and exchanged for a new note.  We recorded a gain of $75,315 on the extinguishment.  


NOTE 8 – RELATED PARTY TRANSACTIONS


Consulting services from Chairman and CEO


Expense for consulting services provided by the Chairman/CEO were $30,000 and $90,000 for the three and nine months ended September 30, 2011, respectively.  No consulting services were provided for 2012, as the Chairman/CEO was converted to an employee in October 2011.


Debt agreements from board member


Entia entered into a promissory note with a board member for a 6% note for $25,000 maturing on December 31, 2013.  The note is reflected on the balance sheet, net of discount in the long term liabilities.


Preferred stock purchase from board member


During the second quarter 2012, a board member purchased 5,000 shares of Series A preferred stock, a $0.001 par value for $5.00 per share.  


NOTE 9 – STOCKHOLDERS’ EQUITY (DEFICIT)


Preferred Stock


On May 26, 2011, our board of directors designated 350,000 shares of preferred stock as Series A preferred stock, $0.001 par value.  The Series A preferred stock is entitled to a liquidation preference in the amount of $5 per share, votes on an as converted basis with the common stock on all matters as to which holders of common stock shall be entitled to vote, and is convertible into common stock on a one-for-ten basis.  


During the third quarter 2012, Entia issued 4,600 shares of Series A preferred stock for cash proceeds of $23,000.


During the second quarter 2012, Entia issued shares of Series A preferred stock for the following:


12,800 shares were issued for cash proceeds of $64,000.  The fair value of the common stock into which the Series A preferred stock is convertible exceeded the allocated purchase price of the Series A preferred stock by $21,139 on the date of issuance, resulting in a beneficial conversion feature.  Entia recognized the beneficial conversion feature as a one-time, non-cash deemed dividend to the holders of the Series A preferred stock on the date of issuance;


1,000 shares were issued in exchange for cancellation of a note payable totaling $10,000; and


7,000 shares valued at $35,000 were issued in exchange for consulting services provided.


During the first quarter 2012, 19,000 shares of Series A preferred stock were issued with a value of $95,000.


Common stock


During the third quarter of 2012, Entia’s board of directors agreed to a special price to current holders of warrants and/or options.  If they committed to exercising their warrants/options, Entia would allow them to convert at $0.40 per share.  This special price was effective only through July 31, 2012.  There were a total of 222,500 warrants exercised for proceeds of $89,000.  $30,000 was received in cash during third quarter 2012 with the remaining $59,000 was exercised by receiving short-term notes with interest ranging from 6% to 20% due before April 2013.  These notes are recorded on the balance sheet as a contra-equity account.  


During the second quarter of 2012, 50,000 shares of common stock valued at $50,000 were issued in exchange for a license agreement.


During the first quarter 2012, 666 shares of common stock were issued to two employees as compensation.  This stock had a fair market value of $400.




13




Stock incentive plan


On September 17, 2010, our Board of Directors adopted the 2010 Stock Incentive Plan (“Plan”). The Plan provides for the grant of options to purchase shares of our common stock, and stock awards consisting of shares of our common stock, to eligible participants, including directors, executive officers, employees and consultants of the Company.  We have reserved 1,500,000 shares of common stock for issuance under the Plan with an annual increase in shares of 50,000 as of January 1 of each year; commencing January 1, 2012.  The fair value of the option grants were estimated at the date of the grants using the Black-Scholes option pricing model with the following assumptions: expected volatility of 233.73% - 248.63%, a risk free rate of 0.84% - 1.15%, and an expected life of 4 - 10 years for the period ended September 30, 2012.  


There were 103,513 authorized shares available under the Plan, and there were options to purchase 807,281 shares of stock exercisable, with a remaining contractual term of 10 years at September 30, 2012.  The weighted average grant date fair value of stock options granted during the quarter ended September 30, 2012 was $0.53.  The weighted average exercise price of stock options granted and exercisable is $0.56 on September 30, 2012.  The aggregate fair value of options vested on September 30, 2012 is $170,342.  Unvested options amounted to $263,227 at September 30, 2012 and there were 20,000 options forfeited with a value of $7,655, none exercised, or expired during the quarter ended September 30, 2012.


At September 30, 2012 there was $762,430 of aggregate intrinsic value of outstanding stock options, including $512,137 of aggregate intrinsic value of exercisable stock options.  Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of third quarter 2012 and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options as of September 30, 2012.  This amount changes based on the fair market value of the Company’s stock.


The Company had $263,227 of total unrecognized compensation cost related to unvested stock options at September 30, 2012, which is expected to be recognized over a weighted average period of 7 years.


Warrants – Consulting Agreements


During the third quarter of 2012, Entia’s board of directors agreed to a special price to current holders of warrants and/or options.  If they committed to exercising their warrants/options, Entia would allow them to convert at $0.40 per share.  This special price was effective only through July 31, 2012.  There were a total of 222,500 warrants exercised for proceeds of $89,000.  $30,000 was received in cash during third quarter 2012 with the remaining $59,000 was exercised by receiving short-term notes with interest ranging from 6% to 20% due before April 2013.


During the second quarter 2012, we issued warrants to purchase 30,496 shares of common stock under agreements for consulting services and warrants to purchase 308,750 shares of common stock under debt agreements to raise capital.  These warrants have an exercise price ranging from $0.45 to $5.00 per share and have an average term of 5.75 years.


During first quarter 2012, we issued warrants to purchase 152 shares of common stock under agreements for consulting services.  These warrants have an exercise price of $5.00 per share and have a term of 7 years.


We use the Black-Scholes option-pricing model to determine the fair value of warrants on the date of grant.  In determining the fair value of warrants, we employed the following key assumptions during the periods ended September 30:


 

 

2012

2011

Risk-Free interest rate

 

0.84% - 1.08%

1.27 - 2.80%

Expected dividend yield

 

0%

0%

Volatility

 

202.65% - 264.48%

183.17 - 187.30%

Expected life

 

5 - 7 years

4 - 10 years

Weighted-average Black-Scholes value of warrants granted

 

$0.56

$2.60



NOTE 10 - COMMITMENTS AND CONTINGENCIES


Leases


On April 4, 2012, Entia Biosciences, Inc. entered into a Commercial Lease agreement with Lanz Properties, LLC for 13,081 square feet of office and warehouse space located at 13565 S.W. Tualatin-Sherwood Road, Suite 800, Sherwood, Oregon 97140.  The



14



new lease commences June 1, 2012 and will terminate on July 31, 2015.  No rent will be payable until October 2012.  The base monthly rental rate will start at $3,160, increasing to $3,260 in October 2013, and then $3,343 in June 2014.  


Entia’s prior two leases for 3,400 square feet at 14889 S.W. Tualatin-Sherwood Road #205, Sherwood, Oregon 97140, had a base monthly rent of $2,400 and ended on May 31, 2012.  Management believes that the new facility offers a better location and configuration for its biotechnology activities and provides significantly more space for manufacturing, fulfillment, and administration over the next three years.


Entia calculated the deferred rent amount related to the long-term lease agreement and determined that the amount to accrue would be immaterial to the financial statements, and thus, decided not to record or disclose this amount.


NOTE 11 – CONCENTRATIONS AND CREDIT RISK


Customers and Credit Concentrations


For the three months ending September 30, 2012, approximately 46.0% of our net sales were to four customers compared to approximately 50.9% for the three months ending September 30, 2011  For the nine months ending September 30, 2012, 52.6% of our net sales were to four customers compared to 48.7% at September 30, 2011.  As of September 30, 2012, accounts receivable for these customers accounted for approximately 68% of total accounts receivable as compared to 36% at December 31, 2011.


Vendor Concentrations


For the three months ending September 30, 2012, approximately 76.3% of our purchases were made from two vendors as compared to approximately 74.7% for the three months ending September 30, 2011. For the nine months ending September 30, 2012, 61.5% of our purchases were made from two vendors as compared to 71.3% for the nine months ending September 30, 2011.


NOTE 12 – SUBSEQUENT EVENTS


There have been no subsequent events as of the date of this filing.



15



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations


Entia Biosciences, Inc. (also referred to as “Entia” or "the Company") is an emerging biotechnology company that has acquired the exclusive world-wide rights to the genetic transporter for Ergothioneine (Ergo), a powerful amino acid that Entia believes is essential to life.  Ergo cannot be synthesized by mammals but is acquired exclusively from the diet and carried by this unique and specific transporter (human gene symbol SLC22A4) to cells throughout the body.  Research studies started during 2011 by Entia have confirmed significant transporter activity in diabetes, arthritis and other serious non-communicable chronic conditions, suggesting an important physiologic roll for Ergo in diseases afflicting millions of people world-wide.


Initially discovered in the early 1900’s, Ergo is a little known antioxidant that is found in naturally high concentrations almost exclusively in mushrooms and other fungi.   Ergo is transferred directly from these sources into the soil where it is taken up by plants and grazing mammals.  For thousands of years, our hunter/gatherer genetics have relied on this process to help maintain adequate levels of Ergo in our blood to fight oxidative stress, DNA damaging free radical reactions, and the onset and progression of disease.   Entia theorizes that during the past century the introduction of modern agricultural practices (chemical fertilizers/insecticides and over tilling of the soil) have been gradually eradicating mushrooms from our farmland and depleting Ergo from the food supply.   During this same period, our dietary habits have been changing (chemical additives and heavily process foods) which Entia believes is further accelerating Ergo deficiency in the general population around the world and may explain the dramatic increase we are now seeing in diabetes, arthritis, neurodegenerative, and other debilitating diseases.  


Ergocalciferol (Vitamin D2) is another genetically-required nutrient found in naturally high concentrations in mushrooms.  Considered essential to life, Vitamin D is a powerful antioxidant that can be ingested from vegetation (D2) and/or synthesized by skin exposure to sunshine (D3) to maintain a healthy immune system and regulate cell differentiation and growth.   Recognized as a common factor in obesity, which affects more than 25% of the US population and 10% of total US medical spending, Vitamin D deficiency is now being linked with a growing number of serious conditions including diabetes, cancer, heart and bowel disease, mental illness, osteoporosis, and Multiple Sclerosis.  Health Canada estimated in 2010 that Vitamin D deficiency affects >85% of all Canadians and normalization could lower the death rate by 16.1% and economic burden by $14 billion/year.  Entia acquired the exclusive rights to technology in 2009 that dramatically increases Vitamin D2 levels in mushrooms using pulsed ultraviolet light, naturally boosting IUs/gram by more than 1000% within seconds.


Entia’s commercialization strategy for this technology is to develop and scientifically validate the benefits of proprietary medical food products, functional ingredients, nutritional supplements and other products containing Ergo and/or Vitamin D2.   Unlike Vitamin D, there are currently no commercially available diagnostic tests that can measure Ergo levels.  Entia believes that its commercialization strategy will be significantly enhanced if it can help to accelerate introduction of a cost effective method of baseline testing to determine deficiency levels in the general population and confirm the need for supplementation with the company’s medical food products.


The non-therapeutic market for consumer “wellness” (vitamins and nutritional supplements) is booming and expected to continue its healthy growth.  Nearly three-quarters of American adults report using dietary supplements, and the market is currently worth nearly $30 billion in the U.S.   Entia believes that the emerging therapeutic market for supplementation (medical foods and functional ingredients) could be much larger in the next decade as the benefits of the technology become more broadly understood and accepted.  The U.S. nutraceutical market is expected to be worth more than $4 billion by 2015, with compound annual growth of 8% from 2011 to 2015.  Additionally, the functional food and drink market is outpacing conventional food and drinks globally by about 4% per year.


Results of Operations for the Three and Nine Months ended September 30, 2012.


Revenues and Cost of Goods Sold:


 

 

For the Three Months Ended September 30,

 

Change

 

 

2012

 

2011

 

$

 

%

Revenues

$

72,604

 

$

108,566

 

$

(35,962)

 

-33.1%

Cost of Goods Sold

23,611

 

15,128

 

8,483 

 

56.1%

 

 

 

 

 

 

 

 

 

 

 

For the Nine Months Ended September 30,

 

Change

 

 

2012

 

2011

 

$

 

%

Revenues

$

263,255

 

$

309,309

 

$

(46,054)

 

-14.9%

Cost of Goods Sold

$

61,738

 

$

100,744

 

$

(39,006)

 

-38.7%



16







Revenues.  Revenues are generated primarily from the sale of our mushroom-based nutraceutical dietary supplement products.  The 33.1% decrease in revenues for the three months ending September 30, 2012 from 2011 was due to the mix of product sales and overall sales decrease during the periods presented.  The 14.9% decrease for nine months ended was due to the large decrease in revenues during the first and third quarter of 2012 as compared with the first and third quarter of 2011.


Cost of Goods Sold.   Cost of goods sold includes raw materials such as nutraceutical mushrooms, as well as production costs for manufacturing our supplement products.  Cost of goods sold for the three months ended September 30, 2012 increased from 2011 due to a more accurate costing system being implemented for our product during 2012.  The decrease in cost of goods sold for the nine months ending September 30, 2011 is due to increased efficiencies at producing product, inventory management and the ability to produce most of the product in-house instead of subcontracting it to third parties.


The following is a summary of certain consolidated statement of operations data for the periods:


Operating Expenses:


 

 

 

 

 

For the Three Months Ended September 30,

 

Change

 

 

 

 

 

2012

 

2011

 

$

 

%

Advertising & promotion expenses

 

$

11,420

 

$

11,419

 

$

 

0.0%

Sales Commissions/consulting fees

 

40,206

 

45,057

 

(4,851)

 

-10.8%

Professional fees

 

 

33,717

 

60,986

 

(27,269)

 

-44.7%

General and Administrative expenses

 

193,676

 

101,318

 

92,358 

 

91.2%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Nine Months Ended September 30,

 

Change

 

 

 

 

 

2012

 

2011

 

$

 

%

Advertising & promotion expenses

 

$

20,862

 

$

82,110

 

$

(61,248)

 

-74.6%

Sales Commissions/consulting fees

 

197,406

 

358,703

 

(161,297)

 

-45.0%

Professional fees

 

 

115,021

 

223,460

 

(108,439)

 

-48.5%

General and Administrative expenses

 

667,240

 

484,462

 

182,778 

 

37.7%



Advertising and promotional expenses.  These costs include costs for promotional products, production fees for marketing materials, costs associated with fulfillment, fees for advertising programs such as ad placement fees, and postage fees for mailing marketing materials.  The decrease from 2011 is due to the decrease in advertising expense by using web-based options that occurred during third quarter 2011.  


Sales Commissions/Consulting fees.  These expenses are comprised of fees incurred by third-party consultants for the provision of administrative, information technology and marketing management services.  The decrease in these expenses from 2011 was due to the smaller amount of costs incurred to compensate third party consultants for services in third quarter 2012 and the reduction in sales persons within the company.  


Professional fees.  These expenses primarily include accounting/auditing fees, legal fees and stock transfer fees.  The decrease in professional fees from 2011 is due primarily to decrease legal and auditing fees in 2012.


General and administrative expenses.  These expenses primarily include compensation, costs related to travel, rent and utilities, insurance, depreciation, product development, payroll and bad debt.  The increase from 2011 is attributable to an increase in stock based compensation and the addition of employees during 2012.  In 2011, Entia had no employees, only consultants.


Inflation


Inflation has not had a significant impact in the current or prior periods.


Significant changes in the number of employees


As of September 30, 2012, we have seven employees, Marvin S. Hausman, M.D., our Chief Executive Officer, Devin Andres our Vice President, three other full and part-time employees and two paid interns.  As our operations expand we anticipate the need to hire additional employees, and contract with additional consultants; however, the exact number is not quantifiable at this time.



17




Liquidity and Capital Resources


At September 30, 2012, cash totaled $14,698, compared to $16,639 at December 31, 2011.  The primary reasons for the net decrease in 2012 are described below.  Working capital was $(708,638) at September 30, 2012, compared to $(291,271) at December 31, 2011.  The change in working capital was due primarily to the maturity date of most of our debt and decrease in cash.  The net change in cash and cash equivalents for the periods presented was comprised of the following:


 

 

 

For the Nine Months Ended September 30,

 

 

 

 

 

2012

 

2011

 

Change

Net cash provided by (used in)

 

 

 

 

 

 

Operating activities

$

(169,789)

 

$

(185,740)

 

$

15,951 

 

Investing activities

(72,221)

 

(30,193)

 

(42,028)

 

Financing activities

240,069 

 

158,843 

 

81,226 



Operating Activities.  The increase in net cash flows used from operating activities was due primarily to a smaller net loss from operating activities and an increase in accounts payable and accrued expenses during the nine months ended September 30, 2012.


Investing Activities.  The increase in net cash flows used from investing activities was due primarily to acquisitions of patents and patents pending and purchase of fixed assets.


Financing Activities.  The increase in net cash flows from financing activities was due primarily to proceeds from the issuance of Series A Preferred Stock and proceeds from sales of common stock.  


Future Liquidity.  We have a history of incurring net losses and negative operating cash flows.  We are also deploying new technologies and continue to develop commercial products and services.  Based on our cash on hand, income from operations and the degree to which our burn rate can be reduced while continuing operations, management believes it has sufficient funds to remain operational through December 2012.


We expect our revenues to increase in the fourth quarter of 2012.  Notwithstanding, we anticipate generating losses in 2012 and therefore we may be unable to continue operations in the future.   In order for us to continue as a going concern and ultimately to achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs.  We have successfully negotiated an extension on all of our debt that was maturing on June 30, 2012 for one year.  We will require additional capital of at least approximately $392,500 to repay debt maturing on June 30, 2013 and we intend to raise the monies by undertaking one or more equity private placements.  We may also pursue re-negotiation and re-structuring of the debt.  However, there can be no assurances that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and at terms acceptable to us, or at all.  The issuance of additional equity or convertible debt securities will also cause dilution to our shareholders.  If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, which could jeopardize our future strategic initiatives and business plans.  For example, a reduction in operating costs could jeopardize our ability to launch, market, and sell new nutraceutical supplement products necessary to grow and sustain our operations.  


Subsequent Events


There have been no subsequent events as of the date of this filing.


Going Concern


We have a history of incurring net losses and net operating cash flow deficits.  We are also developing new technologies related to our organic nutraceutical products.  At September 30, 2012, we had cash and cash equivalents of $14,698.  These conditions raise substantial doubt about our ability to continue as a going concern.  As a result, we anticipate that our cash and cash equivalent balances, anticipated cash flows from operations and anticipated operating cash flows will be sufficient to meet our cash requirements through December 2012.


In order for us to continue as a going concern beyond this point and ultimately to achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs.  The issuance of equity securities will also cause dilution to our shareholders.  If external financing sources of financing are not available or are inadequate to fund our operations, we will



18



be required to reduce operating costs including personnel costs, which could jeopardize our future strategic initiatives and business plans.


Off-Balance Sheet Arrangements


We have no off-balance sheet arrangements.


Critical Accounting Policies and Estimates


Revenue Recognition:  We recognize revenue from product sales once all of the following criteria for revenue recognition have been met: pervasive evidence that an agreement exists; the services have been rendered; the fee is fixed and determinable and not subject to refund or adjustment; and collection of the amount due is reasonable assured.


Item 3. Quantitative and Qualitative Disclosures about Market Risk.


Not applicable.


Item 4.  Controls and Procedures


Evaluation of Disclosure Controls and Procedures


In connection with the preparation of this Quarterly Report on Form 10-Q, an evaluation was carried out by our management, with the participation of our Chief Executive Officer who is also our principal financial and accounting officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of June 30, 2012.  Based on that evaluation, our principal executive officer and principal financial officer concluded that the material weaknesses identified in our management report on internal controls and procedures contained in our Form 10-K for the fiscal year ended December 31, 2011, Item 9A filed on March 30, 2012 still exist, and therefore our disclosure controls and procedures were not effective as of September 30, 2012.


Changes in Internal Control Over Financial Reporting


As of September 30, 2012, there have been no changes in internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) during the quarter ended September 30, 2012, that materially affected, or are reasonably likely to materially affect, our company’s internal control over financial reporting.




19



Part II.OTHER INFORMATION


Item 1.  Legal Proceedings


From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business.  However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.


We are not presently a party to any material litigation, nor to the knowledge of management is any litigation threatened against us, which may materially affect us.


Item 1A.  Risk Factors


See Risk Factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and the discussion above in Part I, Item 2, under " Liquidity and Capital Resources.”


Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds 


We have undertaken a private placement of convertible preferred stock for $1.5 million.  During the third quarter 2012, 4,600 shares of preferred stock were issued with a value of $23,000 for cash.  During the second quarter 2012, 6,800 shares of preferred stock were issued with a value of $34,000 for cash.  10,000 shares of preferred stock were issued with a value of $50,000 for extinguishment of a $10,000 note, for services valued at $35,000 and $5,000 cash.  In addition, 5,000 shares were issued for cash from a related party.  Each preferred share is convertible into 10 shares of common stock.  The issuance of the preferred shares was exempt from registration based on Regulation D, Rule 506 and Section 4(2) and under the Securities Act.


Item 3.  Defaults Upon Senior Securities


None.


Item 4.  Mine Safety Disclosures


Not Applicable.


Item 5.  Other Information


None.


Item 6.  Exhibits 

Exhibit Number

Description of Exhibit

Filed Herewith

Form

Exhibit

Filing Date

 

 

 

 

 

 

3.1

Amended and Restated Articles of Incorporation of Registrant

 

8-K

3.1

10/29/2010

3.2

Amended and Restated Bylaws of Registrant

 

8-K

3.2

09/22/2010

3.3

Amended Articles of Merger Incorporation as currently in effect

 

8-K

3.3

10/13/2008

10.1

Exclusive Option Agreement dated May 1, 2006, between The Penn State Research Foundation and Northwest Medical Research Inc.

 

8-K

10.1

09/04/2008

10.2

Assignment Agreement to the Option Agreement, dated July 31, 2008, among The Penn State Research Foundation, Northwest Medical Research Inc. and Generic Marketing Services, Inc.

 

8-K

10.2

09/04/2008

10.3

Assignment and Assumption Agreement, dated July 31, 2008, between Northwest Medical Research Inc. and Generic Marketing Services, Inc.

 

8-K

10.3

09/04/2008

10.4

Form of Common Stock and Warrant Purchase Agreement

 

8-K

10.1

06/12/2009

10.5

Form of Securities Purchase Agreement

 

8-K

10.1

09/21/2009



20






10.6

$50,000 Promissory Note between TNS and Marvin S. Hausman, M.D. and Philip Sobol dated December 30, 2009

 

8-K

10.1

12/31/2010

10.7

$100,000 Promissory Note between TNS and Larry A. Johnson dated January 12, 2010

 

8-K

10.1

2/24/2010

10.8

$100,000 Promissory Note between TNS and Mark C. Wolf dated February 18, 2010

 

8-K

10.2

2/24/2010

10.9

$50,000 Promissory Note between TNS and Mark C. Wolf dated February 18, 2010

 

10-K

10.9

4/15/2010

10.10

Profit Sharing Agreement between TNS, American Charter & Marketing LLC, and Delta Group Investments, Limited dated March 26, 2010

 

10-K

10.10

4/15/2010

10.11

Form of Common Stock and Warrant Agreement 2010

 

8-K

10.1

12/20/2010

10.12

$312,500 Promissory Note between TNS and Delta Group Investments Limited dated January 26, 2011

 

8-K

10.2

2/22/2010

10.13

Termination of Profit Sharing Agreement dated February 21, 2011

 

8-K

10.1

2/22/2011

10.14

Lease Agreement between TNS and Sherwood Venture LLC dated March 15, 2011

 

8-K

10.1

4/6/2011

10.15

Form of Warrant A Agreement 2010

 

8-K

10.2

12/22/2010

10.16

Form of Warrant B Agreement 2010

 

8-K

10.3

12/22/2010

10.15

Form of Warrant A Agreement 2010

 

8-K

10.2

12/22/2010

10.16

Form of Warrant B Agreement 2010

 

8-K

10.3

12/22/2010

10.17

Asset Purchase Agreement between TNS, FunGuys, LLC and Mark C. Wolf dated May 27, 2011

 

8-K

10.1

3/3/2011

10.18

Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock of Total Nutraceutical Solutions, Inc. dated May 26, 2011.

 

8-K

10.3

3/3/2011

10.19

Employment Agreement between Marvin S. Hausman, M.D. and Total Nutraceutical Solutions, Inc. dated October 28, 2011.

 

8-K

10.1

11/2/2011

10.20

Employment Agreement between Devin Andres and Total Nutraceutical Solutions, Inc. dated October 28, 2011.

 

8-K

10.2

11/2/2011

32.1

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).

X

 

 

 

32.2

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).

X

 

 

 




21



SIGNATURES


In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 

Entia Biosciences, Inc.

 

 

November 14, 2012

By:  

/s/ Marvin Hausman, M.D. 

 

Marvin Hausman, M.D.

Chief Executive Officer

(Principal Executive Officer and Acting Principal Financial and Accounting Officer)





22